中国生物技术2025年美国临床肿瘤学会（ASCO）摘要解读

M UpdateChina Healthcare | Asia PacificChina Biotech: 2025 ASCO Abstract Reactions Morgan Stanley Asia Limited+Jack LinEquity Analyst Jack.Lin@morganstanley.com +852 3963-3746 China HealthcareAsia PacificIndustry ViewAttractiveFor detailed data comparison, see China Healthcare: China Biotech: AACR Takeaways, Out-licensing Update, and ASCO Preview. See inside for additional abstract reactions for MS China Biotech coverage. We share our initial thoughts on the ASCO abstracts, as well as expectations for the main event over May 30-Jun 3. DB-1311 in 3L CRPC - Median rPFS (n=57) continued to demonstrate best-in-class potential at 8.3m (vs. 7.2m previously) with the upper end of CI still not reached at 5.7 months of follow-up (link). Blended Gr3+ TRAE of 40% appears slightly higher than previously reported, and we await breakdown between 6mg/9mg cohorts.DB-1310 in pre-t